Can a 're­dis­cov­ered' drug from In­dia make it big in US im­munol­o­gy space? Dan Brad­bury and his team at Equi­l­li­um want to prove yes

Biotech com­pa­nies typ­i­cal­ly knock on Nas­daq’s doors with sev­er­al rounds of fi­nanc­ing un­der their belt. Equi­l­li­um, how­ev­er, went straight for it.

Hav­ing reaped a $65.4 mil­lion IPO last month, the San Diego-based biotech is emerg­ing from stealth mode to dis­cuss for the first time that atyp­i­cal route — a some­what un­ex­pect­ed one, CEO Dan Brad­bury would add — and the atyp­i­cal arrange­ment that made it pos­si­ble for an op­er­a­tion that on­ly launched 18 months ago.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER